Treatment of type II diabetes: What options have been added to traditional methods?

Postgraduate Medicine

Volumn 99, Issue 3, 1996, Pages 109-122

  Cefalu, William T ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES CONTROL; DIET THERAPY; HUMAN; INSULIN SENSITIVITY; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SULFONYLUREA COMPOUNDS;

EID: 0029989231     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. US Department of Health and Human Services. Diabetes statistics (from National Diabetes information Clearinghouse). Bethesda: Dept of Health and Human Services, 1995 Oct; NIH publication No. 96-236
2. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Lilly lecture 1987. Diabetes 1988;37(6):667-87
3. Klip A, Marette A, Dimitrakoudis D, et al. Effect of diabetes on glucoregulation: from glucose transporters to glucose metabolism in vivo. Diabetes Care 1992;15(11):1747-66
4. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991;14(6):461-9
5. Sowers JR, Standley PR, Ram JL, et al. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993;6(7 Pt 2):260-70S
6. DeFronzo RA, Ferraimini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14(3):173-94
7. Howard G, O'Leary D, Ayad M, et al. Lower insulin sensitivity is related to atherosclerosis in non-diabetics: the Insulin Resistance Atherosclerosis Study (IRAS). (Abstr) Diabetes 1994;43(1):188A
8. American Diabetes Association. Office guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance. Diabetes Care 1995;18(1):4
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86
10. American Diabetes Association. Consensus statement. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989;12(8):573-9
11. Cooppan R. General approach to the treatment of diabetes. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus. 13th ed. Philadelphia: Lea & Febiger, 1994:397-403
12. American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18(11):1510-8
13. American Diabetes Association Task Force on Financing Quality Health Care for Persons with Diabetes. Diabetes outpatient education: the evidence of cost savings. Workshop on approaches to third-party reimbursement for diabetes outpatient education. Alexandria, Va: American Diabetes Association, 1986
14. American Diabetes Association. Position statement. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1994;17(5):519-22
15. American Diabetes Association. Technical review: exercise and NIDDM. Diabetes Care 1993;16(Suppl 2):54-8
16. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321(18): 1231-45 [Erratum, N Engl J Med 1990;322(1):71]
17. Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994;17(12): 1460-4
18. Cefalu WT, Bell-Farrow AD, Wang ZQ, et al. Insulin sensitivity in vivo is improved after glipizide GITS treatment. (Abstr) Diabetes 1995; 44(Suppl 1):397A
19. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15(6):755-72
20. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44(2): 107-12
21. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placeboconrrolled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98(5):443-51
22. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992;15(6):792-805
23. Steiner KE, Lien EL. Hypoglycaemic agents which do not release insulin. Prog Med Chem 1987;24:209-48
24. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13(6):610-30
25. Miller JL, Salman K, Shulman LH, et al. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes. Clin Pharmacol Ther 1993;53(3):380-4
26. Riddle MC, Hart JS, Bouma DJ, et al. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 1989;12(9):623-9
27. Escalante DA, Davidson J, Garber AJ. Maximizing glycemic control: how to achieve normal glycemia while minimizing hyperinsulinemia in insulin-requiring patients with diabetes mellitus. Clin Diabetes 1993; Jan/Feb:3-6
28. Skyler JS. Insulin treatment. In: Lebovitz HE, DeFronzo RA, eds. Therapy for diabetes mellitus and related disorders. Alexandria, Va, American Diabetes Assn, 1991:chap 20